Oxford Nanopore Technologies Ltd

www.nanoporetech.com

Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

news image

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR CPASS™ SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | November 10, 2020

news image

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More

Diagnostics

LUCID DIAGNOSTICS, A SUBSIDIARY OF PAVMED, ANNOUNCED LAUNCH OF VA ESOGUARD® STUDY

Lucid Diagnostics | March 25, 2022

news image

Lucid Diagnostics Inc., a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc, announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center had enrolled their first patient in a Department of Defense ("DoD")- Katarina B. Greer, M.D., an associate professor of medicine at Case Western Reserve University School of Medicine in Cleveland, is the lead investigator of the research. Lucid supplies the...

Read More

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

news image

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More
news image

Industrial Impact

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More
news image

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR CPASS™ SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | November 10, 2020

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More
news image

Diagnostics

LUCID DIAGNOSTICS, A SUBSIDIARY OF PAVMED, ANNOUNCED LAUNCH OF VA ESOGUARD® STUDY

Lucid Diagnostics | March 25, 2022

Lucid Diagnostics Inc., a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc, announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center had enrolled their first patient in a Department of Defense ("DoD")- Katarina B. Greer, M.D., an associate professor of medicine at Case Western Reserve University School of Medicine in Cleveland, is the lead investigator of the research. Lucid supplies the...

Read More
news image

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us